Global Non-Invasive Prenatal Testing (NIPT) Market Analysis and Forecast 2017-2023: Focus on Test Type, Country Analysis, Patent Landscape, and Competitive Landscape

Dublin, May 09, 2017 -- Research and Markets has announced the addition of the "Global Non-Invasive Prenatal Testing (NIPT) Market - Analysis and Forecast (2017-2023) (Focus on Test Type, Country Analysis (Test Volume & Value), APAC Countries by Test Type, Patent Landscape, and Competitive Landscape)" report to their offering.

The research study has segmented the entire NIPT market into test value and volume, and geographical region including detail country analysis which enables the user gain a multi-dimensional view of the market. The research report employs an exhaustive and analytical approach to estimate and understand the market thus provides an all-inclusive insight into various forms of developments, market trends and strategies. While underlining the key driving and restraining factors for the NIPT market, the report also provides a comprehensive understanding in terms of competitive landscape, market share analysis, competitor benchmarking (matrices), and their positioning within the global NIPT market.

The major NIPTs currently available in the global market are MaterniT21 PLUS, Harmony, Panorama, verifi, NIFTY, PrenaTest, IONA, and BambniTest, among others. Of these, Panorama held the largest share of 19% of the market in terms of revenue in 2016, followed by NIFTY with 16%. North America was the largest market for NIPT in 2016 in terms of revenue and volume. The region is expected to retain its leadership position throughout the forecast period as major players in the NIPT market are based in the U.S. (the largest shareholder in North America).

Market growth in Rest of the World (RoW) and Asia Pacific largely depends upon market penetration by the U.S.-based players and emerging indigenous players such as BGI Diagnostics (China). Non-invasive in nature, high accuracy and early detection, and rising awareness are some of the advantages offered by NIPTs as compared to invasive tests. Moreover, factors such as increasing market penetration in a number of countries in Europe and Asia and continuous rise in average maternal age are likely to fuel the growth of the global NIPT market during the forecast period.

The market is driven by product launches and development strategies followed by partnerships and collaborations. Moreover, established healthcare diagnostic companies are acquiring small market players/new entrants to position themselves in the NIPT market. For example, the recent acquisition of Sequenom Inc. by LabCorp in January 2017 has again showcased the need of acquisition of elementary player of the market. Also, Roche acquired Ariosa Diagnostics in 2014 while Illumina acquired Verinata Health in 2014. Due to the nascent stage of the market, the companies should focus on the development of technologically advanced, highly accurate and cost effective tests which can screen and diagnose numerous disorders in the prenatal market scheme.

The existing players should emphasize on the expansion of their business in countries with huge population and high birth rate such as China, India, Brazil, Niger, and other MEA countries. The increasing awareness and need for early diagnosis of genetic disorders will generate a huge market for prenatal tests in the future. The development of pre-implantation diagnosis tests are helping parents in early stage of pregnancy, and is foreseen as a viable opportunity for this market.

Key Topics Covered:

Executive Summary

1. Report Scope & Methodology

2. Market Overview

3. Market Dynamics

4. Major Chromosomal Aneuploidies

5. Competitive Landscape

6. Global NIPT Market, By Test (Volume and Value)

7. Global NIPT Market, By Geography (Volume and Value)

8. End User Perception

9. Company Profiles

• BGI Diagnostics
• Berry Genomics
• Illumina
• LabCorp
• LifeCodexx
• Natera
• Premaitha
• Roche

For more information about this report visit http://www.researchandmarkets.com/research/zpvbnd/global

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Diagnostics, Women's Health